380 participants, including 67 Korean and 메이저 바카라사이트 유니88벳 investors, engage in 420 partnering meetings

Source: Korea Drug Development Fund (메이저 바카라사이트 유니88벳)
Source: Korea Drug Development Fund (메이저 바카라사이트 유니88벳)

[by Yu, Suin] The Korea Drug Development Fund (KDDF) announced on May 29 that the ‘2025 KDDF Global Biotech Showcase,’ held from May 27 to 28 at the Fairmont Ambassador Seoul, concluded successfully, marking a record turnout with the highest number of participating investors to date.

This event was organized to attract 메이저 바카라사이트 유니88벳 investment, expand technology transfer opportunities for promising Korean novel drug development companies, and strengthen the 메이저 바카라사이트 유니88벳 competitiveness of Korea’s biotechnology ecosystem. A total of 380 participants, including 67 leading domestic and international investors, attended the showcase, engaging in active networking and exploring new avenues for collaboration in the field of new drug development.

A total of 420 one-on-one partnering meetings were conducted over the two-day event, representing a 2.5-fold increase compared to the previous year. The 메이저 바카라사이트 유니88벳 employed its proprietary matching program to facilitate efficient meetings between companies and investors and noted a significant improvement in both the level of engagement and the depth of discussion throughout the event.

Notably, the newly introduced ‘Round Table Meeting’ featured an open-discussion format, in which participants freely exchanged views and opinions around a table led by key industry figures. The session fostered active dialogue on critical topics, including investment strategies, new drug development, artificial intelligence and platform technologies, and licensing and public listing.

Noel Jee, partner at Novo Holdings and a participating 메이저 바카라사이트 유니88벳 venture capital (VC) investor at the event, remarked, “Until about four years ago, the Korean market received limited attention from 메이저 바카라사이트 유니88벳 investors. However, interest in Korea’s biotechnology industry has grown significantly in recent years.” He further noted, “Korea possesses many strengths, such as a robust clinical trial environment and well-developed infrastructure, and we anticipate that investment and cooperation initiatives will continue to expand over the next two to three years.”

“I hope today’s discussions will serve as a foundation for tomorrow’s cooperation and innovation,” stated Park Yeong min, CEO of KDDF. “We will continue to offer comprehensive support to ensure that Korea’s drug development capabilities gain greater recognition in the 메이저 바카라사이트 유니88벳 market,” he added.

The business division intends to actively pursue a range of collaborative programs moving forward, aiming to expand the 메이저 바카라사이트 유니88벳 network of Korean biotechnology companies and to establish a solid foundation for their sustainable growth.

저작권자 © 더메이저 바카라사이트 유니88벳 무단전재 및 재배포 금지